{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T11:17:07Z","timestamp":1722165427509},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.eimc.2011.09.013","type":"journal-article","created":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T09:02:49Z","timestamp":1323421369000},"page":"249-256","source":"Crossref","is-referenced-by-count":5,"title":["Dosificaci\u00f3n de antibi\u00f3ticos en el tratamiento de las infecciones por SARM en pacientes con insuficiencia renal aguda sometidos a t\u00e9cnicas continuas de depuraci\u00f3n extrarrenal"],"prefix":"10.1016","volume":"30","author":[{"given":"Esther","family":"Carcelero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Soy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2011.09.013_bib0005","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1046\/j.1523-1755.2002.00509.x","article-title":"Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes","volume":"62","author":"Clermont","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.eimc.2011.09.013_bib0010","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.294.7.813","article-title":"Acute renal failure in critically ill patients: a multinational, multicenter study","volume":"294","author":"Uchino","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2011.09.013_bib0015","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1345\/aph.17105","article-title":"A primer on continuous renal replacement therapy for critically ill patients","volume":"32","author":"Joy","year":"1998","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eimc.2011.09.013_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000170102","article-title":"Dialysis-induced hypotension. A fresh look at pathophysiology","volume":"11","author":"Zucchelli","year":"1993","journal-title":"Blood Purif"},{"key":"10.1016\/j.eimc.2011.09.013_bib0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1086\/592984","article-title":"Incidence rate and variable cost of nosocomial infections in different types of intensive care units","volume":"30","author":"Chen","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.eimc.2011.09.013_bib0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00003246-199401000-00013","article-title":"Influence of nosocomial infection on mortality rate in an intensive care unit","volume":"22","author":"Bueno-Cavanillas","year":"1994","journal-title":"Crit Care Med"},{"key":"10.1016\/j.eimc.2011.09.013_bib0035","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"Internacional study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2011.09.013_bib0040","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJMoa010307","article-title":"Early goal-directed therapy in the treatment of severe sepsis and septic shock","volume":"345","author":"Rivers","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2011.09.013_bib0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jinf.2008.11.003","article-title":"GEIH\/GEMARA\/REIPI. Impact of inappropriate empirical therapy for sepsis due to health care-associated methicillin-resistant Staphylococcus aureus","volume":"58","author":"Rodr\u00edguez-Ba\u00f1o","year":"2009","journal-title":"J Infect"},{"key":"10.1016\/j.eimc.2011.09.013_bib0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.09.013_bib0055","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/00003088-200746120-00003","article-title":"Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy","volume":"46","author":"Pea","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 5","key":"10.1016\/j.eimc.2011.09.013_bib0060","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1086\/431674","article-title":"The pharmacokinetic and pharmacodynamic profile of tigecycline","volume":"41","author":"Meagher","year":"2005","journal-title":"CID"},{"key":"10.1016\/j.eimc.2011.09.013_bib0065","unstructured":"Troy SM, Muralidharan G, Micalizzi M, Mojavarian P, Salacinski L, Raible D. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936) [abstract A-43]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology; 2003. p. 5."},{"key":"10.1016\/j.eimc.2011.09.013_bib0070","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/444500","article-title":"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy","volume":"41","author":"Trotman","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.09.013_bib0075","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00003088-200443040-00003","article-title":"Clinical pharmacokinetics of quinupristin\/dalfopristin","volume":"43","author":"Bearden","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2011.09.013_bib0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-198611040-00001","article-title":"Clinical Pharmacokinetics of Vancomycin","volume":"11","author":"Matzke","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2011.09.013_bib0085","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2165\/00003088-199018030-00002","article-title":"Clinical pharmacokinetics of teicoplanin","volume":"18","author":"Rowland","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2011.09.013_bib0090","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s001340051018","article-title":"Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients","volume":"25","author":"Boereboom","year":"1999","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.eimc.2011.09.013_bib0095","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/clpt.1991.208","article-title":"Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance","volume":"50","author":"Macias","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eimc.2011.09.013_bib0100","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijantimicag.2011.04.010","article-title":"Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients","volume":"38","author":"Chaijamorn","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimc.2011.09.013_bib0105","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1007\/s00134-002-1495-z","article-title":"Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution","volume":"28","author":"Uchino","year":"2002","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.eimc.2011.09.013_bib0110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2125.2004.02143.x","article-title":"Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration","volume":"58","author":"DelDot","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2011.09.013_bib0115","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF01694710","article-title":"Pharmacokinetics of vancomycin during continuous hemodiafiltration","volume":"19","author":"Santr\u00e9","year":"1993","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.eimc.2011.09.013_bib0120","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1007\/s00134-003-1914-9","article-title":"Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration","volume":"29","author":"Yagasaki","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.eimc.2011.09.013_bib0125","first-page":"243","article-title":"Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration","volume":"48","author":"Bellmann","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.eimc.2011.09.013_bib0130","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00007691-200110000-00013","article-title":"Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration","volume":"23","author":"Pea","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.eimc.2011.09.013_bib0135","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/jac\/dkp155","article-title":"Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30min infusion or 2min injection","volume":"64","author":"Chakraborty","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2011.09.013_bib0140","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1053\/j.ajkd.2009.02.017","article-title":"Plasma and peritoneal dialysate levels during daptomycin therapy for peritonitis","volume":"53","author":"Khadzhynov","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.eimc.2011.09.013_bib0145","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/ndt\/gfp704","article-title":"Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study","volume":"25","author":"Kielstein","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.eimc.2011.09.013_bib0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/CCM.0b013e3181fa36fb","article-title":"Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis","volume":"39","author":"Vilay","year":"2011","journal-title":"Crit Care Med"},{"key":"10.1016\/j.eimc.2011.09.013_bib0155","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/jac\/dkg180","article-title":"Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers","volume":"51","author":"Stalker","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2011.09.013_bib0160","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2011.09.013_bib0165","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jac\/dki133","article-title":"Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration","volume":"56","author":"Meyer","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2011.09.013_bib0170","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1053\/j.ajkd.2004.08.032","article-title":"Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases","volume":"44","author":"Pea","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.eimc.2011.09.013_bib0175","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1097\/01.CCM.0000147687.06808.92","article-title":"Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure","volume":"32","author":"Fiaccadori","year":"2004","journal-title":"Crit Care Med"},{"key":"10.1016\/j.eimc.2011.09.013_bib0180","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1053\/j.ajkd.2006.03.037","article-title":"Clearance of linezolid via continuous venovenous hemodiafiltration","volume":"47","author":"Mauro","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.eimc.2011.09.013_bib0185","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1592\/phco.23.8.1071.32874","article-title":"Linezolid clearance during continuous venovenous hemodiafiltration: a case report","volume":"23","author":"Kraft","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.eimc.2011.09.013_bib0190","doi-asserted-by":"crossref","unstructured":"Carcelero E, Soy D, Guerrero L, Poch E, Fern\u00e1ndez J, Castro P, et al. Linezolid pharmacokinetics in patients with acute renal failure undergoing continuous venovenous hemodiafiltration. J Clin Pharmacol. 2011. (en prensa).","DOI":"10.1177\/0091270011417717"},{"key":"10.1016\/j.eimc.2011.09.013_bib0195","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1345\/aph.1P160","article-title":"Trimethoprim\/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration","volume":"44","author":"Curkovic","year":"2010","journal-title":"Ann Pharmacother"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X11003144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X11003144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T17:22:51Z","timestamp":1561051371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X11003144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0213005X11003144"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2011.09.013","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}